Current clinical trials in amyotrophic lateral sclerosis

被引：28
作者：
Bhatt, Jaydeep M. [1 ]
Gordon, Paul H. [1 ]
机构：
[1] Columbia Univ, Dept Neurol, Neurol Inst, Eleanor & Lou Gehrig MDA ALS Res Ctr, New York, NY 10032 USA
来源：
EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2007年 / 16卷 / 08期
基金：
美国国家卫生研究院;
关键词：
amyotrophic lateral sclerosis; clinical trials; excitotoxicity; minocycline; motor neuron degeneration; neuroprotective agents; neurotrophic factors; riluzole;
D O I：
10.1517/13543784.16.8.1197
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Amyotrophic lateral sclerosis is caused by selective degeneration of motor neurons in the brain and spinal cord. There are still no other effective therapies 10 years after the approval of riluzole for the treatment of amyotrophic lateral sclerosis, but advances in drug development and screening are substantially increasing the number of potential therapeutic agents. This review provides an overview of clinical trial methodology in annyotrophic lateral sclerosis followed by a systematic evaluation of drugs that are presently in Phase I, II and III clinical trials. There is an emphasis on the scientific evidence supporting the selection of each drug being tested, as well as on trial design.
引用
收藏
页码：1197 / 1207
页数：11
相关论文
共 92 条
  • [1] Lentiviral-mediated RNA interference
    Abbas-Terki, T
    Blanco-Bose, W
    Déglon, N
    Pralong, W
    Aebischer, P
    [J]. HUMAN GENE THERAPY, 2002, 13 (18) : 2197 - 2201
  • [2] ABITBOL JL, 2006, AMYOTROPH LATERAL S1, V7, P112
  • [3] Therapeutic vaccine for acute and chronic motor neuron diseases: Implications for amyotrophic lateral sclerosis
    Angelov, DN
    Waibel, S
    Guntinas-Lichius, O
    Lenzen, M
    Neiss, WF
    Tomov, TL
    Yoles, E
    Kipnis, J
    Schori, H
    Reuter, A
    Ludolph, A
    Schwartz, M
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (08) : 4790 - 4795
  • [4] [Anonymous], 1874, OEUVRES COMPLE TES
  • [5] VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model
    Azzouz, M
    Ralph, GS
    Storkebaum, E
    Walmsley, LE
    Mitrophanous, KA
    Kingsman, SM
    Carmeliet, P
    Mazarakis, ND
    [J]. NATURE, 2004, 429 (6990) : 413 - 417
  • [6] Protein kinase c isoforms as therapeutic targets in nervous system disease states
    Battaini, F
    [J]. PHARMACOLOGICAL RESEARCH, 2001, 44 (05) : 353 - 361
  • [7] Mitochondria and the pathogenesis of ALS
    Beal, MF
    [J]. BRAIN, 2000, 123 : 1291 - 1292
  • [8] Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease
    Benner, EJ
    Mosley, RL
    Destache, CJ
    Lewis, TB
    Jackson-Lewis, V
    Gorantla, S
    Nemachek, C
    Green, SR
    Przedborski, S
    Gendelman, HE
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (25) : 9435 - 9440
  • [9] A CONTROLLED TRIAL OF RILUZOLE IN AMYOTROPHIC-LATERAL-SCLEROSIS
    BENSIMON, G
    LACOMBLEZ, L
    MEININGER, V
    BOUCHE, P
    DELWAIDE, C
    COURATIER, P
    BLIN, O
    VIADER, F
    PEYROSTPAUL, H
    DAVID, J
    MALOTEAUX, JM
    HUGON, J
    LATERRE, EC
    RASCOL, A
    CLANET, M
    VALLAT, JM
    DUMAS, A
    SERRATRICE, G
    LECHEVALLIER, B
    PEUCH, AJ
    NGUYEN, T
    SHU, C
    BASTIEN, P
    PAPILLON, C
    DURRLEMAN, S
    LOUVEL, E
    GUILLET, P
    LEDOUX, L
    ORVOENFRIJA, E
    DIB, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (09) : 585 - 591
  • [10] RILUZOLE AND EXPERIMENTAL PARKINSONISM - ANTAGONISM OF MPTP-INDUCED DECREASE IN CENTRAL DOPAMINE LEVELS IN MICE
    BOIREAU, A
    DUBEDAT, P
    BORDIER, F
    PENY, C
    MIQUET, JM
    DURAND, G
    MEUNIER, M
    DOBLE, A
    [J]. NEUROREPORT, 1994, 5 (18) : 2657 - 2660
12345678910